◼ Archived
Business
🔮 fades ✓
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharmaceuticals is entering the endocrine disease market with a $10 billion acquisition of Crinetics.
2 trends tracked about this subject — the full history, oldest to newest below.
Vertex Pharmaceuticals is entering the endocrine disease market with a $10 billion acquisition of Crinetics.
Vertex Pharmaceuticals is expanding into endocrinology with a record-breaking $10 billion acquisition of biotech specialist Crinetics.